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Fidaxomicin is sporicidal and may be associated with a reduced time to resolution of
diarrhoea when used to treat patients with Clostridium difficile infection (CDI). This study
investigated whether fidaxomicin for treatment of all patients with CDI reduced
C. difficile environmental contamination. Surfaces in the rooms of 66 hospitalized patients
treated with metronidazole and/or vancomycin and 68 hospitalized patients treated with
fidaxomicin were sampled. Patients treated with fidaxomicin were less likely to contam-
inate their environment (25/68, 36.8%) than patients treated with metronidazole and/or
vancomycin (38/66 57.6%) (P ¼ 0.02). Treatment with fidaxomicin was associated with
reduced environmental contamination with C. difficile.
ª 2015 The Authors. Published by Elsevier Ltd on behalf of the Healthcare Infection
Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1 2Introduction
Fidaxomicin has been licensed for the treatment of Clos-
tridium difficile infection (CDI) since 2011. In-vitro studies
have indicated that fidaxomicin exhibits bactericidal activityr Clinical Infection and
and Guy’s & St Thomas’
ad, London SE1 7EH, UK.
188 3146.
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rg/licenses/by-nc-nd/4.0/).against C. difficile, inhibits outgrowth of spores and inhibits
toxin production.3
Two randomized controlled trials demonstrated significantly
lower recurrence rates in patients treated with fidaxomicin
compared with patients treated with oral vancomycin.4,5 In
one study, the median time to resolution of diarrhoea was
shorter in patients treated with fidaxomicin compared with
patients treated with vancomycin (58 vs 78 h), although this
was not significant.5
These properties could result in less bacterial shedding;
however, to the authors’ knowledge, no studies have investi-
gated the effect of introducing fidaxomicin on environmentalealthcare Infection Society. This is an open access article under the CC
J.S. Biswas et al. / Journal of Hospital Infection 90 (2015) 267e270268contamination. The authors started using fidaxomicin as a first-
line therapy in all adults in October 2012. Previously, metroni-
dazole and/or vancomycin was prescribed according to
severity. Environmental contamination rates were assessed in
the rooms of patients treated with metronidazole and/or van-
comycin and the rooms of patients treated with fidaxomicin.
Methods
Setting
This study was conducted in an academic hospital with 1100
beds, including 180 single rooms. Patients with diarrhoea are
placed in these rooms (with en-suite toilet) until at least 48 h
after return to normal bowel habit, as described previously.6
This study was classed as a service evaluation with ethical
board exemption; as such, patient consent was not sought.
Investigation for CDI
Clinicians are advised to investigate all clinically significant
diarrhoea using GDH enzyme immunoassay (EIA) (C. diff Chek-
60, TechLab, Blacksburg, VA, USA), followed by EIA for toxins
A/B (C. difficile ToxA/B II, TechLab, Blacksburg, VA, USA) and
polymerase chain reaction (PCR) (GeneXpert, Cepheid, Sun-
nyvale, CA, USA). Patients with positive toxin EIA or positive
PCR results are reviewed by an infectious diseases and/or
microbiology physician who makes recommendations on
treatment. If required, treatment consisted of metronidazole
and/or oral vancomycin during the baseline period
(AprileSeptember 2012) and fidaxomicin between October
2012 and June 2014.
Environmental cleaning
Daily cleaning is performed with a chlorine-dioxide-
containing solution (Difficil-S, Clinimax Ltd, Bury St Edmunds,
UK) using microfibre cloths. The rooms of all patients with
C. difficile, meticillin-resistant Staphylococcus aureus or other
resistant organisms are required to undergo deep/terminal
cleaning upon discharge. This comprises standard cleaning as
described above, followed by decontamination with a
hydrogen peroxide vapour (HPV) system (Bioquell UK Ltd,
Andover, UK). No changes to the environmental cleaning and
disinfection policies were made during the study period.
Environmental sampling
Samples were collected between two and four days
following the patient result from four standardized patient
room sites: bed rails, bed controls/call buttons, toilet and
shower area. Samples were collected using cellulose sponges
presoaked in neutralizing buffer (Whatman, Maidstone, UK).
Sponges were rubbed over a 10 cm  10 cm area in two di-
rections at right angles, and placed in Robertson’s cooked meat
broth supplemented with cycloserine, cefoxitin, lysozyme and
sodium taurocholate. Samples were incubated anaerobically
for seven days at 37C as described previously.7 Aliquots of
culture broth were subcultured on to agar containing cyclo-
serine, cefoxitin and fructose (Oxoid, Basingstoke, UK), and
incubated for a further two days. Presumptive colonies wereconfirmed with MALDI-TOF mass spectrometry (Bruker Corp,
Coventry, UK). All isolates underwent PCR ribotyping according
to standard techniques.
Patient demographics (age, sex, community or hospital-
associated infection), markers of severity [peripheral white
cell count, C-reactive protein (CRP), albumin and creatinine;
taking the most extreme value within three days of the labo-
ratory test] and clinical outcomes (30-day all-cause mortality
and length of stay) were recorded. The PCR threshold cycle (Ct)
value was used as a surrogate marker of bacterial load.
Statistical methods
Continuous variables were compared using unpaired t-tests,
and categorical variables were compared using Fisher’s exact
tests.
Results
In total, 66 patients who were treated with metronidazole
and/or vancomycin between April and September 2012 had
environmental sampling performed and were included in the
study. Between October 2012 and June 2014, 68 patients
treated with fidaxomicin had environmental sampling per-
formed and were included in the study. Of the patients who
were treated with metronidazole and/or vancomycin, 42
(63.7%) received metronidazole alone, 23 (34.8%) received
vancomycin alone, and one (1.5%) received both metronidazole
and vancomycin.
There were no significant differences in the demographics
of either patient group (age and sex), whether the infection
was community or hospital-associated, markers of severity
(white cell count, CRP, albumin and creatinine) or 30-day
all-cause mortality. There were no significant differences in
the proportion of patients with a positive toxin EIA and no
difference in the mean PCR Ct values (26.6 for patients treated
with metronidazole and/or vancomycin vs 26 for patients
treated with fidaxomicin), suggesting that the initial bioburden
was similar in both groups. Patients treated with fidaxomicin
had a longer length of stay following diagnosis (median 26 days)
compared with patients treated with metronidazole and/or
vancomycin (median 12 days) (P ¼ 0.01).
Figure 1 summarizes the environmental contamination re-
sults for both patient groups. In total, 38 out of 66 (57.6%)
patients treated with metronidazole and/or vancomycin had
one or more positive environmental cultures compared with 25
of 68 (36.8%) patients treated with fidaxomicin (P ¼ 0.02).
Similarly, when considering all of the sampled environmental
sites, 68 out of 264 (25.8%) were positive in patients treated
with metronidazole and/or vancomycin compared with 47 out
of 272 (17.3%) in patients treated with fidaxomicin (P ¼ 0.02).
Patient isolates were indistinguishable from environmental
isolates on PCR ribotyping in 51 out of 68 (75%) of cases for
patients treated with metronidazole and/or vancomycin, and
38 out of 47 (80.1%) cases for patients treated with fidaxomicin
(P ¼ 0.5).
Discussion
The use of fidaxomicin as a first-line agent for all patients
with CDI was associated with a decrease in environmental
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Figure 1. Environmental contamination rates for patients treated
with vancomycin and/or metronidazole and fidaxomicin.
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from which C. difficile was recovered, and the overall burden
of contamination determined by the proportion of contami-
nated sites. Importantly, there were no significant differences
in patient groups in terms of demographics, mode of acquisi-
tion and severity markers. Additionally, likely bacterial burden
using the PCR Ct value as a surrogate marker was similar in both
groups; other investigators have also used this parameter to
estimate bacterial load.8 The reason for the additional length
of stay for patients treated with fidaxomicin is unclear but
warrants further investigation.
This study has several limitations. Firstly, time to resolution
of diarrhoea was not measured, but may be an important factor
in environmental contamination rates. Instead, sampling was
performed between two and four days following the patient
result, which may have resulted in variation in administration
time of anti-C. difficile therapy. However, it is estimated that
most patients had received at least two full days of therapy
when the environmental samples were taken. Patients are
likely to wait longer to receive fidaxomicin (which is a non-
stock drug and provided from the central pharmacy) than
metronidazole and/or vancomycin (which are stock items on all
wards).
Secondly, the environmental sampling approach was quali-
tative, including a broth enrichment step to improve sensi-
tivity. As such, it was not possible to evaluate differences in the
concentration of contamination on surfaces.
The rate of CDI declined during the study [from 18.25 cases
per 100,000 occupied bed days (OBD) from April to September
2012 to 13.21 cases per 100,000 OBD from October 2012 to June
2014]. Although there were no changes in environmental
cleaning during this period, there were some additional
infection control interventions (particularly around antimi-
crobial stewardship) that were introduced during the course ofthe study. It is possible that the reduction in environmental
contamination was partly due to these additional interventions
rather than use of fidaxomicin.
Not all of the environmental isolates matched the clinical
isolates; overall, 75% and 80.1% of isolates matched in patients
treated with metronidazole and/or vancomycin and fidax-
omicin, respectively. More discriminatory genotyping methods,
such as multi-locus variable number tandem repeat analysis or
whole-genome sequencing, were not performed, and may have
revealed fewer matching isolates. The source of these non-
matching isolates is unclear. However, the most likely source
is from prior occupants who were not recognized to be infected
or colonized with C. difficile, and whose rooms were not
therefore decontaminated with HPV.
A prior room occupant with CDI is a significant risk factor for
CDI acquisition.9 As HPV was used to decontaminate the rooms
of CDI patients, any increased risk for the incoming occupant
associated with higher levels of contamination in the rooms of
patients treated using metronidazole and/or vancomycin
should be mitigated. However, the higher levels of contami-
nation during the patient’s stay are important from an infec-
tion prevention viewpoint, and likely increase the risk of hand
contamination of healthcare workers during patient care.10
Treatment with fidaxomicin was associated with signifi-
cantly decreased environmental contamination compared with
treatment with metronidazole and/or vancomycin. To the au-
thors’ knowledge, this is the first study to describe such an
association. Fidaxomicin may contribute to reduction of sec-
ondary cases of CDI by reducing contamination of the envi-
ronment, although the exact mechanism for this is not known.
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